Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heat-treated bifidobacterium longum ES1
- Development stage
- Unknown
- Lead developer
- Archer Daniels Midland
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Heat-treated Bifidobacterium longum ES1 (HT-ES1) is a postbiotic derived from the Bifidobacterium longum strain CECT 7347. Unlike live probiotics, HT-ES1 consists of heat-inactivated microbial cells that retain biological activity and confer health benefits to the host. Developed by ADM (Biopolis), HT-ES1 is primarily investigated for its ability to modulate the gut microbiota, reinforce the intestinal barrier, and exert anti-inflammatory effects. It has been clinically evaluated for the management of Irritable Bowel Syndrome with Diarrhea (IBS-D) and has shown potential in supporting individuals with gluten-related disorders, such as Celiac disease, by reducing intestinal inflammation and permeability.
- Brand names
- ES1ES-1ES 1
- Other names
- heat-inactivated Bifidobacterium longum ES1HT-B. longum ES1heat-treated Bifidobacterium longum CECT 7347
Beyond the preview
Go deeper on heat-treated bifidobacterium longum ES1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heat-treated bifidobacterium longum ES1.